The novel Akt inhibitor Palomid 529 (P529) enhances the effect of radiotherapy in prostate cancer
about
Mechanistic Insights into Molecular Targeting and Combined Modality Therapy for Aggressive, Localized Prostate CancerRas/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance.Targeting the Akt/mTOR pathway in Brca1-deficient cancers.Hypoxia-induced p53 modulates both apoptosis and radiosensitivity via AKTId1 and Id3 co-expression correlates with clinical outcome in stage III-N2 non-small cell lung cancer patients treated with definitive chemoradiotherapy.RES-529: a PI3K/AKT/mTOR pathway inhibitor that dissociates the mTORC1 and mTORC2 complexes.Radiosensitising agents for the radiotherapy of cancer: novel molecularly targeted approaches.Modulating the tumor microenvironment to increase radiation responsiveness.mTOR pathway in colorectal cancer: an update.Rapamycin passes the torch: a new generation of mTOR inhibitors.Emerging roles of radioresistance in prostate cancer metastasis and radiation therapy.Targeting core (mutated) pathways of high-grade gliomas: challenges of intrinsic resistance and drug efflux.Torc1/Torc2 inhibitor, Palomid 529, enhances radiation response modulating CRM1-mediated survivin function and delaying DNA repair in prostate cancer models.Resveratrol enhances prostate cancer cell response to ionizing radiation. Modulation of the AMPK, Akt and mTOR pathways.Resveratrol enhances radiation sensitivity in prostate cancer by inhibiting cell proliferation and promoting cell senescence and apoptosis.Dual mTORC1 and mTORC2 inhibitor Palomid 529 penetrates the blood-brain barrier without restriction by ABCB1 and ABCG2.The HIV protease and PI3K/Akt inhibitor nelfinavir does not improve the curative effect of fractionated irradiation in PC-3 prostate cancer in vitro and in vivo.
P2860
Q26766638-F36287B6-C695-48DB-AF02-A8B3483A3A87Q34307356-1C882727-1FC4-44E2-BEFE-6447E74F713BQ35023287-7B62DA22-F6BC-4FD3-8947-96EF191DE2A7Q35836156-045B8DAE-B594-4954-A966-C3E1B21A0CCCQ36597275-329FE6E6-E26D-4044-B643-AD4C5302E171Q36939659-8EC2E87D-3380-499E-BC28-5982CF634948Q37489947-0B8ACE90-067C-4734-A34D-DC9FB91BF7C1Q37613364-EFB43056-B225-4D0E-897B-3B72AB6F2A1BQ37649634-7827B86E-52F7-4F03-885C-69F527C84850Q37950771-FD257662-D392-44BC-9DF5-70107348A9B1Q38180344-2B38E730-CF72-4F6E-B518-B5AA17D0775DQ38233105-2B61E2D3-9A0B-411F-8F0D-2F2309E45ACDQ39006052-F0A364EB-1D14-47BB-8974-28BC6676A419Q39156783-5771F6E1-BD52-48EA-988E-127DB38D7299Q39379898-838E6977-70FD-4CB3-BDA7-19FF6D3A0686Q48151074-8CFD84C9-57CB-4B70-9432-53A50EAE6BC5Q53596358-68572EB5-FB4D-4A5F-8F50-43BD264D7F38
P2860
The novel Akt inhibitor Palomid 529 (P529) enhances the effect of radiotherapy in prostate cancer
description
2009 nî lūn-bûn
@nan
2009 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի մարտին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
The novel Akt inhibitor Palomi ...... adiotherapy in prostate cancer
@ast
The novel Akt inhibitor Palomi ...... adiotherapy in prostate cancer
@en
The novel Akt inhibitor Palomi ...... adiotherapy in prostate cancer
@nl
type
label
The novel Akt inhibitor Palomi ...... adiotherapy in prostate cancer
@ast
The novel Akt inhibitor Palomi ...... adiotherapy in prostate cancer
@en
The novel Akt inhibitor Palomi ...... adiotherapy in prostate cancer
@nl
prefLabel
The novel Akt inhibitor Palomi ...... adiotherapy in prostate cancer
@ast
The novel Akt inhibitor Palomi ...... adiotherapy in prostate cancer
@en
The novel Akt inhibitor Palomi ...... adiotherapy in prostate cancer
@nl
P2093
P2860
P356
P1476
The novel Akt inhibitor Palomi ...... adiotherapy in prostate cancer
@en
P2093
J A Diaz-Gonzalez
O Gonzalez-Moreno
P A Nguewa
P2860
P2888
P304
P356
10.1038/SJ.BJC.6604938
P407
P50
P577
2009-03-24T00:00:00Z
P5875
P6179
1028296960